• Selective IRAP Inhibitors from Bestatin Derivatives: Structu

  2026-07-09

  This study introduces α-hydroxy-β-amino acid derivatives of Bestatin as highly selective, nanomolar inhibitors of insulin-regulated aminopeptidase (IRAP). The research provides a new synthetic route, crystallographic evidence, and demonstrates unprecedented selectivity and potency, offering valuable chemical tools for aminopeptidase-targeted research.

• Sprayable Hydrogel Nanoparticles for Localized Etoposide Del

  2026-07-09

  This study introduces a bioadhesive, sprayable hydrogel system embedding etoposide and olaparib nanocrystals for post-surgical, localized delivery to brain tumors. The approach demonstrates improved distribution, biocompatibility, and sustained release, addressing key challenges in glioblastoma therapy.

• Pexmetinib (ARRY-614): Precision Cytokine Inhibition Workflo

  2026-07-08

  Pexmetinib (ARRY-614) stands out as a dual inhibitor for robust suppression of inflammatory cytokine synthesis, offering translational power in myelodysplastic syndromes research. This article delivers actionable protocols, troubleshooting insights, and the latest reference-driven innovations to maximize experimental reproducibility and specificity.

• tFUS Modulates Nespas/miR-383-3p/SHP2 in Post-Stroke Neuroin

  2026-07-08

  This study reveals that transcranial focused ultrasound stimulation (tFUS) alleviates NLRP3-driven neuroinflammation after ischemic stroke by activating the Nespas/miR-383-3p/SHP2 signaling axis in microglia. These findings identify a mechanistic link between noninvasive neuromodulation and microglial inflammatory regulation, highlighting SHP2 as a pivotal target for therapeutic intervention in post-stroke neuroinflammation.

• Tetrahydromagnolol: Applied Workflows for Peripheral CB2 Res

  2026-07-07

  Tetrahydromagnolol empowers precision dissection of peripheral CB2 signaling in advanced analgesic and anti-inflammatory models, with dual GPR55 antagonism for unique pathway mapping. This guide delivers actionable protocols, troubleshooting insights, and practical translation of recent GPCR metastasis research for maximizing APExBIO’s selective agonist in cannabinoid-focused experiments.

• Neuroligin 1 Loss in Striatal D2-MSNs Drives Repetitive Beha

  2026-07-07

  This study uncovers that loss of Neuroligin 1 in striatal D2 receptor-expressing medium spiny neurons (D2-MSNs) leads to their hyperactivation, resulting in increased repetitive behaviors characteristic of autism spectrum disorder (ASD). Single-nucleus RNA sequencing and functional assays demonstrate that PKC overactivation underlies these phenotypes, offering mechanistic insight and highlighting potential intervention points for core ASD symptoms.

• PP2A-Mediated Autophagy Drives Candida albicans Biofilm Resi

  2026-07-06

  The referenced study uncovers the central role of protein phosphatase 2A (PP2A) in regulating autophagy-driven drug resistance within Candida albicans biofilms. By elucidating the molecular mechanisms linking PP2A, ATG protein phosphorylation, and antifungal susceptibility, the work provides a valuable mechanistic target for overcoming biofilm-associated resistance.

• α2-AR Agonists for Immune Modulation in Osteosarcoma Recurre

  2026-07-06

  The reference study pioneers the use of α2-adrenergic receptor agonists delivered via thermo-sensitive hydrogels to mitigate immune rejection and tumor recurrence in osteosarcoma. By mechanistically linking α2-AR activation to enhanced CD8+ T cell responses and improved clinical outcomes, the research sets a new direction for post-surgical immunomodulatory strategies.

• Acetylcysteine in Advanced Redox and Tumor-Stroma Research

  2026-07-05

  Acetylcysteine (N-acetyl-L-cysteine) is a linchpin reagent for dissecting oxidative stress, chemoresistance, and mucosal biology in cutting-edge disease models. This article details robust protocols, cross-validates use-cases from tumor-stroma to neurodegeneration, and delivers troubleshooting strategies to maximize reproducibility and insight.

• RSL3: Glutathione Peroxidase 4 Inhibitor in Ferroptosis Rese

  2026-07-04

  RSL3 is redefining ferroptosis research by enabling precise, rapid induction of iron-dependent cell death in cancer models. Its selective GPX4 inhibition and robust performance in RAS-driven tumor systems make it indispensable for translational cancer biology and radiosensitization workflows.

• Syringin Enhances Sunitinib Efficacy in Renal Cell Carcinoma

  2026-07-03

  This study demonstrates that Syringin, a natural product, inhibits renal cell carcinoma (RCC) cell proliferation and migration, promotes apoptosis, and enhances sensitivity to sunitinib through EGFR/PI3K/Akt pathway modulation. These results highlight Syringin’s potential as a research tool for overcoming drug resistance in RCC and advancing targeted therapy strategies.

• Optimizing Immune Assays with EZ Cap™ OVA mRNA (SKU R1027)

  2026-07-03

  This GEO-driven article explores real-world challenges in immune response assays and demonstrates how EZ Cap™ OVA mRNA (SKU R1027) provides reproducible, Cap 1-structured ovalbumin transcripts for advanced immunology, gene expression, and vaccine development workflows. Readers will discover evidence-based strategies to enhance reliability, mitigate inflammatory artifacts, and streamline protocol optimization using this rigorously validated reagent.

• Carvacrol: Precision Modulation of Cell Cycle and Redox Path

  2026-07-02

  Explore how Carvacrol (5-isopropyl-2-methylphenol) enables advanced cell cycle and redox signaling research. This article reveals mechanistic insights and practical assay implications, providing a unique perspective beyond standard protocols.

• Dinaciclib (SCH727965): Precision CDK Inhibition for Cancer

  2026-07-02

  Explore how Dinaciclib (SCH727965) advances oncology research by targeting cyclin-dependent kinases and enabling the study of tissue boundary dynamics in cancer. This article offers a deeper mechanistic and assay-focused perspective, building on recent developmental biology insights.

• 3-Bromopyruvate Reverses Cetuximab Resistance via Autophagy-

  2026-07-01

  The referenced study identifies a novel approach to overcoming cetuximab resistance in colorectal cancer by co-administering 3-bromopyruvate, which triggers autophagy-dependent ferroptosis and apoptosis. These mechanistic insights advance the understanding of drug resistance in KRAS/BRAF-mutant and acquired-resistant colorectal cancer, offering new avenues for therapeutic intervention and research assay design.

452 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page